Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2019-03-14 AGM Information
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Ensol Biosciences. It contains the meeting agenda, details on voting rights, and management's reference materials (경영참고사항) including business overviews and pipeline status. This type of document is standard for proxy solicitation and providing information to shareholders ahead of an Annual General Meeting, which falls under the Proxy Solicitation & Information Statement category.
2019-03-14 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by Ensol Biosciences. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits) for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of the agenda and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2019-03-13 Korean
기타주요경영사항(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Ensol Biosciences regarding the approval of a Phase 1 clinical trial for their osteoarthritis treatment, ENGEDI1000. It follows the standard format for 'Major Management Matters' (자율공시) in the Korean market, which is used to announce significant operational developments such as clinical trial approvals. Since it does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2018-12-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for Ensol Biosciences. It specifies the record date, the period of suspension, and the reason (preparing for the 18th Annual General Meeting). Since this is a regulatory announcement regarding corporate administrative procedures and does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2018-12-13 Korean
지정자문인선임계약의해지
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the termination of a designated advisor contract (지정자문인 선임계약의 해지) for Ensol Biosciences. It does not fit into specific categories like financial reports, M&A, or director dealings. As it is a formal regulatory notification of a corporate event that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2018-12-11 Korean
지정자문인선임계약의체결
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the appointment of a new designated advisor (NH Investment & Securities) following the termination of a previous contract. It does not constitute a full financial report, proxy, or governance document, but rather a specific corporate regulatory disclosure regarding operational/advisory changes. As it does not fit into specific categories like M&A, Board changes, or Share issues, it falls under the general regulatory filing category.
2018-12-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.